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Abstract 
Coma and disorders of consciousness (DoC) are highly prevalent and constitute a burden for patients, families, and 
society worldwide. As part of the Curing Coma Campaign, the Neurocritical Care Society partnered with the National 
Institutes of Health to organize a symposium bringing together experts from all over the world to develop research 
targets for DoC. The conference was structured along six domains: (1) defining endotype/phenotypes, (2) biomarkers, 
(3) proof‑of‑concept clinical trials, (4) neuroprognostication, (5) long‑term recovery, and (6) large datasets. This pro‑
ceedings paper presents actionable research targets based on the presentations and discussions that occurred at the 
conference. We summarize the background, main research gaps, overall goals, the panel discussion of the approach, 
limitations and challenges, and deliverables that were identified.
Keywords: Coma, Consciousness, Electrophysiology, Magnetic resonance imaging, Biomarkers
Introduction
Coma and disorders of consciousness (DoC) result from 
a wide range of etiologies and are prevalent worldwide. 
In 2019, the Neurocritical Care Society (NCS) launched 
the Curing Coma Campaign, with the goal of improving 
the outcomes of patients with coma and DoC. The Cur-
ing Coma Campaign Scientific Advisory Council identi-
fied initial scientific challenges for the campaign [1] and 
partnered with the National Institutes of Health (NIH) 
to organize a symposium to bring together DoC experts 
from all over the world. These experts were invited on the 
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basis of content expertise, ensuring diversity of specialty 
backgrounds to provide a forum for open scientific dis-
cussion and designate research targets for the NIH and 
the Curing Coma Campaign.
This NIH symposium was originally planned as a 
2-day in-person meeting on the NIH campus. However, 
because of coronavirus disease 2019 (COVID-19)-related 
travel restrictions, it took place as a 2-day virtual meeting 
on September 9–10, 2020. This meeting was conceptual-
ized as the first of several meetings to facilitate a broad 
discussion between stakeholders in the field, including 
scientific leaders, NIH representatives, industry part-
ners, and patient advocates. The conference was struc-
tured along six domains (see Supplemental Figure  1): 
(1) defining endotypes/phenotypes, (2) biomarkers, (3) 
proof-of-concept clinical trials, (4) neuroprognostica-
tion, (5) long-term recovery, and (6) large data sets. A 
total of 471 participants registered for the meeting (376 
practicing in North America, 40 in Europe, 23 in Central 
or South America, 11 in Asia, 10 in Africa, and 8 in the 
Middle East). Eleven industry representatives and sixteen 
National Institute of Neurological Disorders and Stroke 
representatives attended. Thirty-two percent of all reg-
istered participants were women. Engagement with the 
conference was high despite the online format, as dem-
onstrated by attendance, which exceeded 250 both days. 
The discussion of topics was facilitated by using an online 
platform that supported an active discussion between 
presenters and participants.
The goal of this proceedings paper is to distill the 
essence of the presentations and discussions that 
occurred and to translate these into actionable research 
targets. For each topic, we summarize the background, 
main research gaps, overall goals, the panel discussion of 




Current prognostication models for brain injury that 
focus only on motor response and overt evidence of cog-
nition provide limited ability to predict outcomes, with 
the best models having only 70–80% discrimination 
[2]. Treatments for acute brain injury based on pheno-
type classification are also greatly limited, with harmful, 
uncertain, or inconsistent outcomes in clinical trials [3–
5]. Furthermore, most clinical trials have not successfully 
translated preclinical evidence of efficacy into success-
ful therapies for humans. Thus, 60–85% of randomized 
controlled clinical trials (RCTs) conducted in the setting 
of acute brain injury have produced inconclusive results 
[3–5].
The limitations in accuracy of prognostication and 
efficacy of therapy point to the larger issue of human 
biological heterogeneity. Converging research demon-
strates the limitations of phenotype-driven detection, 
diagnosis, classification, treatment selection, and prog-
nosis for patients with severe brain injury and DoC. 
These approaches may lump biologically heterogeneous 
patients into a single phenotypic category. Successfully 
addressing the goal of restoring consciousness and pro-
moting meaningful recovery requires precisely character-
izing states of vigilance that distinguish the underlying 
etiology or pathophysiologic mechanisms affecting con-
sciousness and/or responsiveness. By describing, defin-
ing, and classifying DoC in a manner that is more closely 
aligned with biological mechanisms, we can design more 
effective RCTs and increase the likelihood of discovering 
therapies that promote recovery from coma.
Clinical evaluations that focus on motor function and 
overt cognition fail to capture subtle but highly mean-
ingful differences between patients [6]. One example of 
this is patients with covert cognition or cognitive motor 
dissociation (CMD). Covert cognitive states may provide 
a stronger basis for treatment and prognostication, but 
they require advanced imaging or neurophysiology to be 
identified [7–10].
Patients who share a specific mechanism or cluster 
of mechanisms that lead to the phenotype of coma are 
said to belong to an endotype. More generally, an endo-
type can be defined as a constellation of disease features 
anchored in a biological mechanism or pathway that 
is associated with a predictable disease trajectory and 
treatment response. An endotype is intrinsically more 
homogeneous than the larger phenotypically defined 
population. A wide variety of genetic and nongenetic 
determinants shape biological mechanisms that drive 
coma. Thus, multiple patients may be in a coma (the 
phenotype), but each might have a different disease tra-
jectory, recovery potential, and treatment response 
depending on the underlying endotype. Each endotype 
will require a nuanced approach to diagnosis and treat-
ment that would not be applicable on the phenotypic 
scale. The potential for endotypes to transform classifica-
tion and treatment has been demonstrated in a number 
of domains, including cancer, asthma, and multiple scle-
rosis. Endotypes are a fundamental principle in person-
alized (precision) medicine because they may form the 
foundation for prognostic enrichment, in which partici-
pants are selected on the basis of the likelihood that they 
will experience a specific outcome, and for predictive 
enrichment, in which patients are selected on the basis of 
the likelihood that they will respond to an intervention 
[11–20].
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Main Research Gap (Current State)
Heterogenous pathological states with different under-
lying mechanisms may be imprecisely distinguished by 
the clinician. This imprecision leads to errors in diagno-
sis, prognostication, and treatment, yielding poor patient 
outcomes.
The overall goal is to increase diagnostic precision, 
build accurate prognostic models, predict therapeutic 
responsiveness, and help create proof-of-concept clini-
cal trials by leveraging accurate prognostic and predictive 
enrichment. This approach will allow smaller mechanis-
tically homogenous groupings of individuals who will 
benefit substantially more from specific treatments than 
the larger heterogeneous classification based on clinical 
phenotypes. The expectation is that this approach would 
increase the likelihood of recovery when treating patients 
with coma and DoC.
Panel Discussion of the Approach
  • Endotypes need to be characterized within the 
framework of the underlying, biological, mechanistic 
causes of the DoC, ranging from neural networks to 
biochemistry.
  • Endotypes will require widely available techniques; 
in addition, a role exists for advanced imaging, elec-
trophysiological, and other specialized tools, some of 
which have yet to be developed. The approach will 
include comprehensively applying existing and novel 
tools (e.g., imaging, high-dimensional data sets, sta-
tistical models, analytic techniques) that accurately 
assess functional and structural neural pathways 
related to consciousness and generate appropriate 
biological hypotheses.
  • An example of the complexity of endotype charac-
terization is the use of machine learning to analyze 
electroencephalography (EEG) or functional mag-
netic resonance imaging (fMRI) responses to diag-
nose CMD, which cannot be diagnosed by clinical 
examination alone. CMD is not an endotype per se, 
but it could be a feature characterizing a subgroup of 
patients who behaviorally are not overtly following 
commands. Taken together with subgroup-specific 
commonalities in network dysfunction, treatment 
response, and long-term outcomes, CMD could be 
a defining feature in one or several endotypes [7–10, 
21–23]. Stated otherwise, CMD considered as a pure 
phenomenological state without connection to a spe-
cific biological mechanism would not alone consti-
tute an endotype.
  • Predictive enrichment in clinical trials: developing 
endotypes to identify patients who have high or low 
likelihood to benefit from an intervention will allow 
for selective sampling for a specific RCT and will 
increase the probability that an effective intervention 
to treat DoC will be discovered.
Limitations/Challenges
  • Endotypes should be axiomatic (i.e., mechanistically 
driven, associated with outcomes and with a treat-
ment response): endotypes not meeting these mini-
mum criteria are unlikely to be useful in the clini-
cal domain and should not be the focus of research 
unless novel therapeutics are likely to leverage these 
mechanisms.
  • Definitions and nomenclature: A review of the litera-
ture indicates that there is a high degree of inconsist-
ency in the use of the terms (e.g., phenotype, subphe-
notype, endotype, endophenotype). We propose here 
an intuitive working definition of endotype that will 
need to be vetted, validated, and accepted. Concep-
tual validity: although the endotype paradigm has 
been explored in other medical domains and seems 
biologically plausible, research is needed to demon-
strate their significance in patients with severe brain 
injury/DoC.
  • Practical considerations: the group raised the issue 
of feasibility, relevance, and implementation of endo-
types in the clinical setting and in the coma science 
community.
  • There is a nonstatic nature of features within endo-
types, in part, because they combine different bio-
markers [24, 25] or biological processes into a sin-
gle determinant factor (e.g., seizure activity, covert 
consciousness). To adjust for this dynamism when 
endotyping patients, researchers should implement 
clustering algorithms and be aware that a patient’s 
changing status may lead to endotype shifts [10, 21, 
26–30]. For example, the patient’s condition in the 
intensive care unit (ICU) is rapidly evolving because 
of dynamic changes in the underlying biological 
mechanisms, and that evolution could be reflected in 
changes in endotype. This dynamism also, however, 
affords potential advantages, such as monitoring of 
duration of coma as an intermediate biomarker or 
assessing of endotypes as time-varying covariates.
  • Validation: the group identified validation of endo-
types, in light of the underlying biology, recovery 
probability, and response to intervention, as a major 
challenge.
  • Censoring outcomes through premature with-
drawal of life support is a confounder of research 




There is a need to develop novel endotypes based on a 
mechanistic biological model of DoC that are not con-
sidered in current clinical treatment settings. These 
endotypes will inform therapeutic approaches based on 
personalized interventions for DoC to increase the rate 
of positive outcomes (i.e., regained consciousness, func-
tional independence, improved patient-centered out-
comes) among patients with DoC.
Biomarkers
Background
Biomarkers are considered any measurements, including 
chemical, physical, or biological (cellular, molecular), that 
relate to a biological system or the interaction between 
biological systems [35]. Currently available diagnostic 
biomarkers do not reliably detect preserved brain net-
works that may support the recovery of consciousness, 
and early prognostic biomarkers do not reliably predict 
outcomes [36, 37]. Because of these failings, prognos-
tication is an uncertain art for clinicians treating DoC 
in the ICU and beyond. Yet many significant treatment 
decisions are made on the basis of uncertain prognoses. 
Incorrect prognosis may lead to premature withdrawal 
of life-sustaining therapy (WLST) or to the maintenance 
of individuals in a severely disabled state against their 
wishes. Indeed, many patients experiencing traumatic 
brain injury (TBI) die of WLST, despite only a portion of 
these patients demonstrating biomarkers associated with 
failure to recover consciousness [34, 38]. A quarter of 
patients with hypoxic-ischemic injury who died of WLST 
would have survived, and 16% might have made a func-
tional recovery by the time of discharge, on the basis of 
their prognoses [39]. Early evidence has shown promise 
for magnetic resonance imaging (MRI) [7–9] and EEG 
[10, 40, 41] patterns that may identify individuals with 
covert consciousness (i.e., purposeful response to stimuli 
otherwise missed by behavioral assessments) [42, 43]. 
Biomarkers of covert consciousness may improve prog-
nostic capabilities for patients with coma [10]. Similarly, 
biomarkers of covert cortical processing (i.e., association 
cortex responses to language otherwise missed by behav-
ioral assessments) also may predict long-term functional 
outcomes [44]. A combination of model-based and data-
driven analyses may enhance mechanistic understanding 
of DoC [37].
Main Research Gap (Current State)
There is a lack of reliable and reproducible biomarkers 
for patients with DoC to assist in prognostication and 
serve as targets for treatments applied in clinical practice, 
as well as those tested in RCTs, to promote recovery of 
consciousness.
The overall goal is to develop a mechanistic approach 
to methodology, phenotyping, outcomes studies, and 
trial design that is anchored in biomarkers that serve as 
diagnostic, prognostic, monitoring, or descriptive meas-
ures in patients with DoC.
Panel Discussion of the Approach
The Curing Coma Campaign Coma Science Work-
ing Group has identified five potential therapeutic 
approaches: pharmacological, electromagnetic, mechani-
cal, sensory, and regenerative. Each provides unique 
opportunities to identify prognostic or therapeutic bio-
markers. Proposed biomarkers can be split into four 
domains: molecular and cellular, imaging, electrophysiol-
ogy, and transcranial magnetic stimulation and electro-
encephalography (TMS-EEG).
  • Molecular and cellular biomarkers aim to detect neu-
ronal and glial function, injury, death, recovery, and 
potential survival [45–48]. Molecular and cellular 
biomarkers include genetic and epigenetic proteins 
and cells/cellular functional assays indicative of cellu-
lar function, viability, and death. There are too many 
molecular and cellular biomarkers that have been 
proposed or implicated to comprehensively review 
them here, but likely a combination of markers, 
rather than a single one, will end up being relevant.
  • Imaging biomarkers aim to map structural and 
functional elements of the brain, including large-
scale networks. Fifteen to twenty percent of patients 
without signs of responsiveness, detected by either 
the Glasgow Coma Scale or Coma Recovery Scale, 
Revised, will demonstrate covert consciousness on 
fMRI [43]. Mapping of functional connectivity by 
using resting state MRI (e.g., characterization of 
default mode network connectivity) may help dis-
tinguish consciousness states [21, 49–53] but alone 
is not sufficient to predict recovery of consciousness 
[50, 54, 55] and should be studied along with other 
networks that contribute to consciousness. Ongo-
ing studies are using such connectivity biomarkers 
to select patients for targeted therapies to promote 
recovery of consciousness [56–58].
  • Electrophysiological biomarkers can be used to 
detect CMD [59]. EEG can be used at the bedside to 
detect command-following [10, 40, 41, 60] and cov-
ert cortical processing [44, 61] in patients who do not 
show behavioral evidence of purposeful responses. 
EEG can also be used to develop biomarkers of cel-
lular preservation that relate to outcomes, such as 
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features within burst suppression patterns, that allow 
for the identification of patients with and without a 
chance to recover [62–64].
  • TMS-EEG biomarkers aim to objectively measure 
brain responses to direct cortical stimulation. This 
technique bypasses afferent sensory and efferent 
motor systems, which may be damaged in patients 
with DoC. TMS-EEG is based on an information the-
ory that posits that conscious experience is at once 
highly integrated and differentiated, with this combi-
nation resulting in a complex system [65]. To meas-
ure these complex systems, a perturbation approach 
is most helpful to track the system’s response [66]. 
In practice, the brain is stimulated noninvasively via 
transcranial magnetic stimulation (TMS), and the 
brain’s response is measured with EEG. Recent work 
has proposed a “perturbational complexity index,” in 
which the numerical value is correlated with changes 
in consciousness, suggesting value as a marker of 
consciousness [67–69].
Limitations/Challenges
  • Ideal biomarkers for coma science should be safe 
(i.e., minimally invasive), feasible, practical (i.e., have 
a timely turnaround), and widely available. They 
should allow for accurate prognosis or goal-directed 
therapy and have therapeutic implications for either 
disease process or pathophysiology.
  • Biomarkers will need to have analytical validity, clini-
cal validity, and clinical utility established [70].
  • The timing and source of sample collection, the mol-
ecules targeted, handling and processing procedures, 
and the end point of interest (e.g., etiology of coma, 
prognosis) need to be defined [71].
  • Confounders in biomarker measurement that need 
to be considered include the impact of physiologic 
states and interventions on biomarkers. Targeted 
temperature management may affect biomarker 
pharmacodynamics, and sedation may affect EEG 
and fMRI results.
  • Biases of investigators who are particularly invested 
in certain biomarkers need to be considered because 
they also may influence the goals of care decision-
making processes. One of the challenges will be to 
temper the overinterpretation by families of results 
from proposed biomarker tests.
  • The development of new tools must be integrated 
within the context of existing, albeit insufficient, bio-
markers. Experimental measures need to be care-
fully disaggregated from proven tools in the coma 
research repertoire so that the accepted measures 
can assist in validating the new tools. It will be vital 
to address whether, and when, information from new 
tools should be shared with families, because this 
creates a risk of biasing the results (e.g., detection of 
CMD may influence the family’s WLST decision).
  • Extrapolation from highly specialized centers to gen-
eral practice needs to be taken into account. Coma 
science needs specialized care centers in which ana-
lytic tools are made widely available in a systematic, 
standardized way. Gaps in diagnostic, prognostic, 
treatment, and rehabilitation equipment and tech-
niques extend beyond economically advantaged 
countries. Inequities from diagnosis to treatment and 
rehabilitation are a critical issue nationally and inter-
nationally.
Deliverables
There is a need for accurate, reliable, and reproducible 
biomarkers for patients with DoC that allow for more 




Proof-of-concept clinical trials of consciousness-pro-
moting therapies have been performed mostly in the 
subacute and chronic stages of DoC [72]. However, 
early interventions may offer opportunities to promote 
recovery of consciousness during critical and acute care 
phases of treatment. Development of early interven-
tions for use in the ICU may prevent premature WLST, 
facilitate self-expression, decrease ICU-related com-
plications, and increase access to rehabilitative care. 
Conversely, early-stage clinical trials may also disprove 
promising theoretical interventions that have not yet 
been fully evaluated in clinical settings. Reasons for the 
failure of proof-of-concept clinical trials, particularly in 
acute care settings, include heterogeneity of the popu-
lation (including the need for better early endotyping), 
inadequate power, use of nonspecific assessments, timing 
of the intervention, and failure to account for a variety of 
individual mitigating factors (e.g., underlying physiology, 
systemic illness, comorbidities, drug interactions, timing 
and dosage of therapies) [73]. Additionally, the impact of 
the context of health care delivery and treatments may 
present unique challenges for clinical trials regarding 
psychosocial aspects of care, cultural/religious beliefs, 
and availability of resources throughout recovery. Over 
the past 2 decades, coma research has focused largely 
on diagnosis and prognosis to understand mechanisms 
of spontaneous recovery of consciousness; yet there has 
been little attention to mechanisms of induced recovery 
of consciousness. Throughout the continuum of care, 
coma researchers must carefully consider these aspects 
and design more effective clinical trials of therapies at all 
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stages of DoC. A recent search of ClinicalTrials.gov for 
trials that are registered as being “in progress” used the 
search terms “consciousness disorder, coma, or disorders 
of consciousness” and found 73 trials of DoC evaluating 
treatment, assessment, or prognosis techniques (Clinical-
Trials.gov accessed September 6, 2020), with few evaluat-
ing DoC throughout the continuum of care.
Main Research Gap (Current State)
Patients with DoC or coma in the ICU and subacute to 
chronic setting are often overlooked in clinical trials, 
undermining the development of reliable prognostic 
tools and treatments.
The overall goal is to offer accurate prognostication 
and treatment strategies that promote recovery of con-
sciousness throughout the continuum of care to as many 
patients as possible.
Panel Discussion of the Approach
  • Addressing the research gap: Researchers need to 
design proof-of-concept trials that focus on identi-
fying biomarkers and neurophysiological techniques 
that will help diagnose, prognose, treat, and cure 
coma in patients. Interventional trials that aim at 
promoting recovery should be based on a mechanis-
tic understanding of DoC.
  • Patient selection: Both endotypes and phenotypes 
should be taken into account in clinical trial design. 
For example, individuals in minimally conscious 
states are more responsive to treatment than those 
with unresponsive wakefulness syndrome. This 
observation highlights the opportunities of predictive 
enrichment strategies to maximize clinical trial suc-
cess for specific populations.
  • Tested intervention: A mechanistic understanding 
of DoC should inform the tested intervention. One 
approach is use of the mesocircuit model, which 
allows researchers to identify areas affected by severe 
brain injury and the cascading effects on the system 
of consciousness. Depending on the affected area, 
different pharmacological and nonpharmacological 
treatments are available, including, but not limited 
to, amantadine [74], apomorphine, zolpidem [75, 
76], TMS [77–84], transcranial direct current stimu-
lation [85–91], deep brain stimulation [92, 93], low-
intensity pulsed ultrasound, and vagal nerve or other 
sensory stimulation [94–96]. Specifically, within trial 
designs, investigators should consider and evaluate 
the benefits and limitations of combination therapies 
[72, 90]. RCTs may focus on regeneration of lost or 
broken circuits after TBI [77–79, 85, 86]. These tech-
niques often seek to leverage the untapped synergis-
tic potential of combination approaches. For exam-
ple, TMS may be more efficacious when combined 
with a pharmacologic stimulant. Combination thera-
pies to fix broken pathways could be defined on an 
individualized basis based on findings of a patient’s 
neurophysiologic, neuroimaging, genetic, or omics 
assessment (see “Defining Endotypes/Phenotypes” 
section for details) combined with an ever-increasing 
understanding of neurological pathways.
  • Timing of treatment: Although early treatment may 
be critical to the recovery of consciousness, research-
ers of chronic DoC may often allow for time after 
the injury to decrease the confounding possibility of 
spontaneous recovery [77–80, 86–89, 97]. Exact tim-
ing for treatment initiation is typically determined by 
clinicians and researchers on an individualized basis. 
It is influenced by a combination of factors (e.g., past 
experience, patient status, time from injury). During 
the hyperacute and acute phases, with active inflam-
matory changes and secondary injury, researchers 
often collect data but hesitate to begin treatment to 
avoid causing further harm. The optimal start time, 
duration, and number of repetitions of an interven-
tion needs to be investigated [73]. When defining 
optimal timing, the individual patient’s neurologic 
injury and systemic illness need to be considered.
  • Biomarkers in clinical trials (see “Biomarkers” sec-
tion for an overview): Clinical trials may be greatly 
improved by adding biomarkers, both as proxies to 
response and as identifiers for subpopulations (e.g., 
endotypes). Molecular and cellular biomarkers could 
serve researchers in conjunction with behavioral, 
electrophysiological, and imaging measures to both 
identify promising candidates to support recovery 
and track responses to investigated interventions. 
Although some common data elements (CDEs) may 
be shared with other similar disorders, many will be 
unique to coma. The larger the population-based 
group from which data are collected, the more ver-
satile the data’s predictive capabilities. In addition, 
the sequence of tracking biomarkers from genome 
and molecules to populations is critical, and coma 
researchers can work from both ends: clinicians can 
start at the treatment population and work down 
toward genomic and molecular levels, whereas 
researchers can start at the genomic and molecular 
level and work up to the population of interest. This 
two-pronged translational and reverse-translational 
approach may expedite the process of identifying the 
best biomarkers for coma treatment and prognosis.
  • Outcome measures: A mechanistic approach to clini-
cal trial design requires new tools to identify pre-
served brain network connections, the ability to map 
the human brain networks essential for conscious-
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ness, the ability to repeatedly assess brain networks 
starting from the acute care phase of treatment, per-
sonalized connectome mapping tools and biomark-
ers, and targeted personalized treatments. Research-
ers agree that a multimodal approach best tracks the 
outcomes of patients receiving treatments. Proof-
of-concept trials with small sample sizes applying 
physiological proxy markers (e.g., EEG enrichment) 
as outcome measures may allow for identification 
of promising treatment avenues before larger trials 
requiring hundreds of patients and clinical outcomes 
become feasible. To then evaluate effects of treat-
ment, the primary measure should include standard-
ized evaluation of behavioral assessment, preferably 
the Coma Recovery Scale, Revised, and patient-cen-
tered outcomes, such as quality of life (QOL) meas-
ures. Neuroimaging and electrophysiological scans 
can then be used as secondary treatment assess-
ments.
  • Improving trial design and logistics: Adaptive clini-
cal trials, in which results can change the design of 
subsequent doses or trial arms, hold promise for the 
evolving understanding of coma. Longitudinal test–
retest designs allow for alteration of drug dose, dura-
tion of therapy, dose and duration of electricity, and 
range of potential stimulation targets in a Bayesian-
adaptive manner. Such an adaptive study was con-
ducted among patients with COVID-19 (Randomized 
Embedded Multifactorial Adaptive Platform for 
Community-acquired Pneumonia  [REMAP-CAP]) 
[98] and allowed for rapid development of treatments 
on the basis of interim analysis. The established clini-
cal trial networks allow for efficient and rapid testing 
of novel interventions. This approach would be useful 
in a cohort of patients with coma, particularly among 
proof-of-concept trials that are already seeking to 
point the field in the correct direction rather than to 
serve as a final study of potential prognostic tools or 
treatments. The concept of pragmatism in clinical tri-
als is crucial because it promotes later translation of 
trial findings into clinical practice. A role for the NCS 
Curing Coma Campaign to facilitate use of a master 
protocol could facilitate the interoperability of adap-
tive study data.
  • Treatment standards: Establishing so-called baseline 
treatment standards for coma remains an important 
priority given current practice variations, particularly 
those surrounding WLST. As a criterion for enroll-
ment in DoC and coma trials, requiring an intent to 
provide aggressive care and postpone WLST orders 
for a predetermined time frame after the injury lead-
ing to the DoC could alleviate concerns about early 
patient loss in acute-phase trials.
Limitations/Challenges
Barriers for the development of strong proof-of-concept 
trials for curing coma science include lack of proper 
endotyping, lack of quality measurement tools for thera-
peutic response, need to account for spontaneous con-
sciousness recovery, need for control groups, and lack of 
accounting for socioeconomic factors, local environment 
and resources, and cultural variation.
  • Novelty of treatments: Essentially, all treatments cur-
rently used in patients with coma are repurposed 
from other pathologies and disorders. Basic and 
preclinical efforts should focus on identifying prom-
ising novel therapeutic approaches to cure coma. 
Translational scientists should help introduce and 
evaluate these in the clinical context of the ICU and 
post-acute-care setting. Close bidirectional commu-
nication between scientists who focus on clinical, 
translational, preclinical, and basic science aspects 
of coma science will be fundamental in achieving the 
stated goals. This bidirectional dialogue may be con-
ceptualized in a top-down and bottom-up analogy 
as a translational and reverse-translational approach 
that needs to be central to future funding initiatives.
  • Treatments may not work for all: Pharmacologi-
cal treatments often work only in a small portion of 
the population treated [75], or they work to improve 
recovery only when they are being administered, and 
improvements disappear after treatment is stopped 
[74]. Nonpharmacological treatments often show 
limited clinical or neurophysiological effects or have 
highly variable effect sizes. Brain stimulation treat-
ment trials have shown varied improvement rates 
depending on the treatment area, with the most 
promising target appearing to be the prefrontal cor-
tex. In addition, findings from the stimulation stud-
ies suggest that individuals in minimally conscious 
states respond better than those in vegetative/unre-
sponsive wakefulness states. Thus, personalized care 
approaches that take into account individual injuries, 
pathways, genetics, and omics are needed.
  • Variability in trials: Variability among patients and 
in the diagnostic and management approaches of 
different clinical centers is a major challenge in tri-
als of coma treatments. Such variability was recently 
highlighted by the results of the Point PRevalence In 
Neurocritical CarE (PRINCE) study, an observational 
prospective investigation of the practice of neuro-
critical care, which included patients with coma [99, 
100]. This variability may result from equipment or 
staffing availability or differences in comfort with 
procedures across clinical centers. Consensus about 
endotyping of patients will be required to minimize 
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patient variability in clinical trials. On the other 
hand, it may be detrimental to force clinical centers 
to follow overly rigid and detailed protocols because 
this approach may lead to the failure of a treatment 
at one site that succeeded at another. Additionally, 
variability in research infrastructure and health care 
service delivery infrastructure that does not support 
investigations of treatments/prognosis throughout 
the continuum of care and across treatment settings 
is of concern. For example, not all health centers have 
on-site inpatient or outpatient brain injury rehabili-
tation units within their health system. Patients may 
be enrolled into a clinical trial in the critical care or 
acute care setting but then be transferred to reha-
bilitation settings outside health systems or to inde-
pendent facilities that may not have the research 
infrastructure to support continued participation in 
a clinical trial. Local experts should be able to use the 
techniques with which they are most comfortable, 
but arrangements do need to be made so that out-
comes will be comparable between centers.
Deliverables
A key deliverable is to develop trials that define biomark-
ers, end points, and feasible treatment approaches that 
build on clearly defined patient-based phenotypes and 
endotypes. There is a need for the design of adaptive, 
exploratory interventional trials that inform development 
of larger pragmatic trials to identify interventions that 
support recovery of consciousness throughout the con-
tinuum of care and improve patient-centered outcomes. 
Simple master protocols could facilitate development and 
use of these deliverables. Once effective interventions are 
identified, further work by using an implementation sci-




Prognostication herewith refers to the ability of clinicians 
to provide surrogate decision-makers with an outlook 
regarding a patient’s future: the potential for recovery, the 
likelihood for disability, and the prospects for awakening 
from coma. Prognostication requires a synthesis of both 
data and clinical experience to inform critical decisions 
by surrogate decision-makers [101]. To this end, improv-
ing the accuracy of prognostication is an important aim 
in research focused on descriptions of clinical predictors, 
characterization of imaging findings, and the develop-
ment of blood-based biomarkers [102].
Prognostication seeks to accurately predict whether 
a patient will awaken and whether they will achieve a 
satisfactory QOL consistent with their values and pref-
erences. To achieve this, investigators must speak the 
same language as defined by CDEs. For example, “awak-
ening” or “following commands” may be defined in dif-
ferent ways, as emphasized by recent work highlighting 
the CMD detected by EEG [10], fMRI [9], or multidi-
mensional clinical assessments [9, 103]. Efforts to define 
CDEs specific to DoC are underway [1].
Yet improvements in prognostic precision are often 
hindered by medical decisions regarding patient triage, 
care limitations, or WLST. Decisions for WLST limit 
the unbiased study of the natural trajectories of recovery 
and the ability to compare these trajectories to those of 
patients who ultimately recover from coma [38, 39, 104]. 
WLST decisions after cardiac arrest are made within 
72 h in as many as 63% of patients, despite findings that 
nearly one third of patients experience delayed awaken-
ing at a median of 93  h following arrest [39, 105]. The 
implications for this are grave: after cardiac arrest, early 
WLST results in an estimated excess of 2300 deaths in 
the United States each year; nearly two thirds of these 
patients might have had functional recovery if allowed to 
survive [39]. Yet significant variability exists in the rates 
of WLST worldwide [100]. After severe TBI, the rates of 
WLST vary broadly across centers [34], and extraneous 
factors unrelated to the medical conditions of patients 
may even play a role in these decisions, including geo-
graphic region, race, payment status, and other fac-
tors [106]. Ultimately, WLST decisions may result in a 
self-fulfilling prophecy in which false certainty about an 
outcome leads independently to an increase in the prob-
ability of that outcome [107].
Typically, prognostic considerations center on mortal-
ity and functional disability. However, satisfactory out-
come after awakening from coma should ideally hinge on 
QOL, which is based on the individual patient’s values 
and preferences [108]. Existing research uses common 
functional outcome scales, such as the modified Rankin 
Scale or the Glasgow Outcome Scale, which focus on a 
limited set of disabilities, such as difficulties in walking 
or performing activities of daily living. These, by their 
nature, do not capture QOL, nor do they account for the 
preferences or values of patients or their families.
Recent work has highlighted cognitive or mental health 
disabilities that develop after critical illness, termed the 
“post-intensive-care syndrome” [109, 110], which may 
impact QOL. However, the majority of studies focused 
on cognitive or mental health outcome end points after 
critical illness have excluded patients with brain injuries 
[111]. Up to 20% of patients requiring care in a neuro-
ICU subsequently exhibit cognitive impairment, and 
more than one third have at least moderate problems 
with anxiety or depression [112]. Those with significant 
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cognitive or physical disability cannot be evaluated by 
using traditional neuropsychological testing. In a study 
of patient-reported outcomes after stroke, only 11.5% 
of those able to participate had a modified Rankin Scale 
score of 3 or greater [113]. The combined impacts of 
brain injury and critical illness on multidimensional out-
comes, including physical functioning, cognition, and 
mental health, after recovery from coma have not been 
adequately studied.
Main Research Gap (Current State)
Coma prognostication struggles to define numerous 
important parameters. Major gaps include defining 
the end points, ascertaining and accounting for WLST 
in coma research, defining meaningful outcomes for 
patients and clinicians, and establishing the validity and 
timing for implementation of prognostic tools. In addi-
tion, current prediction models contain high levels of 
uncertainty and imprecision due to a lack of complexity 
and multiple sources of bias. How to properly and effec-
tively formulate and communicate prognostic judgments 
to families is also unknown. Physicians view prognostica-
tion as one of the most difficult parts of their profession 
[114, 115]; however, they receive little to no training in 
it, and no guidelines for how to communicate prognosis 
have been developed.
The overall goal is to develop tools that allow for accu-
rate prognostication of well-defined, relevant end points 
for patients with DoC and to better understand the opti-
mal methods for communicating prognosis to surrogate 
decision-makers.
Panel Discussion of the Approach
  • Standardization: There is a clear need to develop 
CDEs for established or promising diagnostic evalu-
ations (both clinical and ancillary) and to define the 
optimal time window for these evaluations. There is 
a need to create or refine diagnostic modalities that 
add the greatest prognostic value at the lowest pos-
sible cost. No single test will have sufficient prognos-
tic power to stand alone in predicting recovery from 
coma [116]. Therefore, many candidate tests and data 
will need to be evaluated simultaneously, with an aim 
toward multivariate model development.
  • Accuracy: It is critical to reduce the uncertainty 
and imprecision of existing prediction models. In 
a study of outcome after intracerebral hemorrhage, 
nurses and attending physicians predicted 3-month 
patient outcome more reliably than the validated 
intracerebral hemorrhage score or predictors of 
functional outcome (e.g., Functional Outcome in 
Patients With Primary Intracerebral Hemorrhage 
(FUNC) Score) [117]. This difference in predictive 
accuracy may be due to a number of factors that 
models do not capture, including preexisting con-
ditions, post acute care, and patient support sys-
tems. Models developed from clinical trial data are 
further biased by rigid exclusionary criteria, limit-
ing generalizability across a heterogeneous popu-
lation experiencing DoC. This is a particular issue 
for machine learning or other artificial intelligence 
approaches because algorithms created with biased 
data will produce biased results [118].
  • Validation: Prognostic tools need to be developed 
by using a sufficient volume of clinical information 
to ensure statistically robust models with adequate 
discrimination. Accomplishing this requires a com-
prehensive set of clinical data from both the acute- 
and post-acute-care environments across multiple 
centers. Coma science should practically focus on 
identifying predictors that incrementally enhance the 
prognostic accuracy of validated models.
  • Calibration: To overcome uncertainty within these 
models, prognostic tools require careful calibration 
[119], a measure of how closely observed outcome 
occurs in relation to model predictions. A systematic 
review of prediction models for outcome following 
TBI highlighted the substantial variability in reported 
measures of calibration, with nearly half of all models 
lacking calibration statistics [119]. Clinicians should 
be careful to avoid models for which calibration is 
not known, and coma science research will require 
transparency in both model validation and calibra-
tion.
  • Versioning: As the clinical field of coma science 
evolves, models may not account for updated treat-
ment approaches (e.g., targeted temperature manage-
ment) and subsequently may generate inaccurate or 
unreliable predictions. In this context, approaches 
should consider models that are adaptive to new data 
in real time and can continuously update their prog-
nostic modeling [120].
  • Patient-centered outcomes: Coma research will ben-
efit from moving away from using dichotomized out-
comes as an end point [121]. Instead, future studies 
should examine more granular outcomes focused on 
measures that are important to patients and based 
ideally on each individual’s values and preferences. 
Patients’ perspectives are known to change before 
and after disability, resulting in a “disability paradox” 
[122]. Despite a high rate of functional disability, 
most patients treated with craniotomy for ischemic 
stroke reported being satisfied with life [123].
  • Demographic factors, such as age and sex, need to be 
taken into account for prognostic modeling.
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  • Comorbidities: Medical comorbidities and their 
severity are critical determinants of patient outcome 
and should be taken into account in prognostic tools 
[124–126]. Premorbid cognition, mental health, and 
personality are under-ascertained yet may similarly 
contribute to patient-centered outcomes [127, 128]. 
Coma science research will benefit from refining 
methods to comprehensively evaluate the patient’s 
comorbid status.
  • Early WLST: Methods to reliably ascertain and sta-
tistically address WLST in patients with DoC are 
important. Efforts to study outcomes in populations 
with high mortality [129] should include considera-
tions for when death results from medical decision-
making. Additional considerations include protocol-
ized approaches to limit inappropriately early WLST 
within the context of clinical study design to avoid 
confounding results or designing studies for popula-
tions within cultures or societies that do not practice 
WLST to the same degree.
  • Communicating outcome: Clinicians face a schism 
between their implicit conceptualization of good out-
come and the definitions brought by the patients and 
their families [108]. Clinicians may bring their per-
sonal biases to their perspective on what is consid-
ered a good outcome for patients [130, 131]. To avoid 
this bias, clinicians and researchers must increase 
their own awareness of the discordance between 
what clinicians think families should receive in terms 
of information and support and what families actual 
need [114]. Numerous factors may contribute to this 
discordance in communication and decision-mak-
ing [114, 132], and the existing gaps in communi-
cation cannot be filled until clinicians have a better 
understanding of current prognostic communication 
practices. Clinicians should encourage families and 
surrogates to express a patient’s own values and pref-
erences and then modify their prognostic communi-
cation on the basis of these [133].
Limitations/Challenges
  • Population-based data: Current prognostic tools 
are based on large aggregated patient cohorts and 
not on individualized measures. Hence, outcome 
assessments historically have lacked consideration of 
patient-specific outcomes of interest. Although pop-
ulation-based data are needed for statistical power, 
unmet challenges include curating comprehensive 
clinical data anchored by CDEs and a better under-
standing of biologically relevant and patient-centered 
end points.
  • Bias: Unmeasured bias in clinician to decision-maker 
relationships and communication may confound 
predictions. As new prognostic tools are developed, 
researchers need to avoid introducing personal 
or data biases during the design process. A criti-
cal source of bias that touches both limitations may 
occur during communication between clinicians 
and patient surrogates. New tools are needed to har-
monize prognostic communication to ensure that 
patients’ cultural and social desires are considered 
during assessment and treatment decision-making 
[133, 134]. Prognostic tools are meant to serve not 
only clinicians but also families, who must make 
decisions about the continued care of their loved 
ones [133]. One qualitative study of patients with 
TBI found that patient surrogates preferred numeric 
prognostic probabilities, whereas physicians tended 
to provide qualitative prognosis, in part, because of 
their underestimation of families’ ability to under-
stand them [114]. Adding to this complexity are 
unspoken frustrations surrogates feel about uncer-
tainty and unintentional perceptions of certainty cre-
ated by physicians [114]. For patients with DoC, this 
is particularly important, and the best methods to 
reduce the bias introduced by how prognostic com-
munication is approached are currently unknown.
  • Communication: On the basis of a policy statement 
from leading critical care societies, communication 
with surrogates and families should not be limited 
to a single meeting [133]. Instead, clinicians should 
build trust and form relationships through frequent 
contact with families, helping them understand 
the evolving condition of the patient and discuss-
ing both treatment options and potential outcomes 
[133, 135]. Meeting regularly with families may be 
difficult for clinicians who are already overburdened 
in their tasks and overstretched in their time. How-
ever, this open communication is recommended by 
critical care societies and the Institute of Medicine 
[133, 136]. The clinician–family relationship should 
include the option for families to obtain second opin-
ions from unbiased clinicians. Another key element 
of open communication, commonly requested by 
families, is clinician humility in admitting what infor-
mation is uncertain about a patient’s prognosis or 
treatment [114, 137]. Finally, clinicians should strive 
to be open with families—not only about treatment 
but also about any issues (such as cultural differ-
ences, past experiences, racism, and more) that may 
complicate communication itself [138].
  • Nonmedical factors in clinical care: Clinicians are not 
ideally equipped to determine nonmedical aspects 
of prognosis, which include social support, spiritual 
beliefs, and socioeconomic factors. An interprofes-
sional approach (including social workers and pas-
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toral care) has been recognized as a key component 
in providing high-quality critical care to complex and 
diverse patients [139–141]. Institutional support for 
these aspects of care are often limited, with care bur-
den falling to patients and their families. The process 
of organ transplantation includes a framework for 
considering the nonmedical aspects of care. [142]. 
The evaluation of psychosocial support structures 
available to transplant patients has been well estab-
lished. By contrast, there is little understanding of the 
structures of support for patients with acute brain 
injury [143].
  • Nonmedical factors in coma science: coma science 
similarly should seek to better quantify social sup-
port, spiritual and religious influences, personal pri-
orities, social and cultural values, and socioeconomic 
status when considering prognosis.
Deliverables
There is a need to develop (1) accurate, reliable, and 
reproducible prognostic tools for patients with DoC and 
(2) empirically grounded interventions for high-quality 
prognostic communication that promotes shared deci-
sion-making between clinicians and decision-makers.
Long‑Term Recovery
Background
Survival of patients with coma who previously would 
have died is now common because of improvements in 
early resuscitation, interventions, and ICU manage-
ment. TBI outcomes have improved through advances 
in prehospital triage, rehabilitation care, and compliance 
with published clinical treatment guidelines [144, 145]. 
In addition, survivors of cardiac arrest with hypoxic-
ischemic brain injury are a new population for neu-
rorehabilitation specialists to treat because of increased 
survival secondary to mainstream use of therapeutic 
hypothermia and through public access defibrillation 
efforts and compression-only resuscitation education 
[146, 147]. Evidence cited in the 2018 American Acad-
emy of Neurology, American Congress of Rehabilitation 
Medicine, and National Institute on Disability, Inde-
pendent Living, and Rehabilitation Research practice 
guideline update on DoC makes clear that recovery from 
coma continues longer than previously believed, leading 
to meaningful functional improvement in a substantial 
minority of those affected [148]. The potential for good 
recovery in those with DoC supports the overarching 
goal of prospectively studying long-term recovery trajec-
tories for this population.
Acute treatment of coma and other DoC appropriately 
focuses on short-term survival and recovery of gross 
neurological function but often fails to consider changes 
that occur during the post acute course, ultimately influ-
encing long-term outcome. This can result in under-
estimation of prognosis and inappropriate treatment 
decisions. In the 1994 New England Journal of Medicine 
report on the persistent vegetative state, outcome only 
extended to 1  year after treatment [149]. A few facili-
ties have developed specialized programs for patients 
with DoC, but admissions are constrained by fiscally 
driven gatekeeping policies, providing limited opportu-
nity for systematic outcomes research on this population. 
Patients without detectable signs of recovery at the time 
of acute care discharge may be thought to be destined for 
unfavorable recovery and, thus, may not be referred to 
or accepted into rehabilitation centers. Many are routed 
to nursing facilities and home care settings that are ill-
equipped to manage the complex medical and neurobe-
havioral consequences of the injury.
There is a need for evidence-based post acute care that 
spans a variety of settings. A study of early functional 
outcomes of 396 patients with traumatic DoC and with-
out the ability to follow commands who were admitted to 
inpatient rehabilitation showed that 68% of patients were 
able to follow commands, 23% of patients had recovered 
from posttraumatic amnesia, and 7–14% of patients were 
independent on a range of self-care and mobility tasks 
(dependent on skill area assessed) prior to rehabilitation 
discharge. There is also an imbalance in funded research 
for patients with traumatic versus nontraumatic injuries, 
leading to a dearth of data regarding recovery in patients 
with nontraumatic DoC.
Active medical management by clinicians with exper-
tise in brain injury reduces the rate of new complications 
in patients with DoC [150]. Acute care physiatry input 
can help initiate early DoC prognostication efforts, pre-
vent complications, support early efforts to improve level 
of consciousness, and promote safe transitions of care 
[151].
Research conducted on long-term functional outcome 
after TBI through the TBI Model System Program found 
that by 5  years post injury, 74% of patients who were 
admitted to inpatient rehabilitation and unable to fol-
low commands had regained this ability, approximately 
20% were able to live without in-home supervision, and 
19% were rated as capable of competitive employment 
[152]. Measurable gains in independence continued out 
to 10  years in a portion of the same cohort [153], par-
ticularly those who recovered command-following dur-
ing their rehabilitation stay. The recovery trajectory 
for those with nontraumatic DoC differs but is less well 
understood. Pooled analysis of patients with prolonged 
nontraumatic vegetative state/unresponsive wakefulness 
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syndrome suggests that 17% will recover consciousness at 
6 months and an additional 7.5% beyond 6 months [154].
These findings indicate that there is substantial recov-
ery over a long period of time for a sizable minority of 
individuals with prolonged DoC. Although surviving 
patients often have a high comorbidity burden, effectively 
managing comorbidity appears to improve long-term 
outcome [150, 151]. Emerging treatments in the field may 
enhance these positive long-term outcomes further [72]. 
This potential for long-term recovery needs to be consid-
ered when delivering acute care early after the injury as 
well as when triaging patients into the ideal care setting 
to support long-term recovery.
Main Research Gap (Current State)
Although understanding of the long-term recovery tra-
jectory of patients with DoC has expanded considerably 
over the last decade, predicting the recovery trajectory 
and functional outcome remains imprecise in individual 
patients, particularly in the very early period when many 
urgent treatment decisions are being made.
Overall Goal
Long-term, researchers need to characterize the clinical 
trajectory of a broad range of DoC patients over a long 
time frame, taking patient heterogeneity and contextual 
factors into account. As a short-term goal, studying those 
with good and poor recovery after DoC may be a critical 
first step to help demonstrate and define the biomarkers, 
early treatments, and personal or environmental factors 
that represent, enhance, and discern potential for favora-
ble outcome.
Panel Discussion of the Approach
To be successful, longitudinal outcome research involv-
ing patients with DoC must address the following 
considerations:
  • Combating pessimism: A challenge of long-term 
recovery is promoting optimism in the clinical team 
responsible for caring for the patient. The neurocriti-
cal care team should partner with other disciplines, 
including neurorehabilitation specialists and social 
workers. These partnerships extend the breadth of 
knowledge necessary to ensure accurate diagnosis, 
improve outcome prediction and prognostic coun-
seling, identify short- and long-term care needs, and 
establish comprehensive treatment regimens. This 
approach fosters a more thorough understanding of 
the patient’s condition and the probability of further 
recovery, which can boost the optimism of the neu-
rocritical care team and sustain high engagement in 
care.
  • Longitudinal outcome data: Investigations of long-
term outcome following severe brain injury have his-
torically employed 6- or 12-month study end points. 
In 1994, the authors of a major review [149, 155] were 
able to find outcome data later than 12  months in 
less than 50 patients with TBI. The challenges asso-
ciated with obtaining long-term outcome data from 
patients with DoC make it difficult to build large 
data sets necessary for tracking the natural history 
of recovery. Point-of-care or other carefully designed 
longitudinal studies are needed to acquire long-term 
data, and study end points should exceed 12 months 
because there is growing evidence that meaningful 
recovery can continue for at least 10 years [153].
  • Conducting pragmatic clinical trials that investigate 
the context of care delivery (i.e., inpatient rehabili-
tation facility vs. home vs. nursing home facility) on 
long-term recovery of patients with DoC.
  • Large multicenter clinical trials: The field needs large 
RCTs to assess any of the proposed mechanisms of 
treatment for both short- and long-term outcomes. 
However, large trials alone will not solve a number of 
structural data insufficiencies, such as survivor bias, 
diversity of injury etiologies, and the many aspects of 
social determinants of health. These can be addressed 
by using strategies that may include oversampling 
for underrepresented groups, provision of rehabili-
tation for all enrolled, and standardized acute- and 
post-acute-care treatment models. Recruiting large 
samples of patients with DoC will require a network 
of sites for recruitment, especially to ensure a large 
enough population to apply endotypes.
  • Ethical questions of equity in clinical trial participa-
tion of patients with DoC, autonomy of decision-
making, and the implications of CMD need to be dis-
cussed, particularly if long-term care is required.
  • Impact of cultural perspectives on neurorecovery and 
disability: The DoC patient population is culturally 
diverse, which means that patients and surrogates 
have distinct sets of values, customs, and cultures 
and a variety of perspectives on health, wellness, life, 
and disability. These beliefs impact multiple aspects 
of care, including access to services, treatment 
opportunities, community engagement, and QOL. 
This work may require the assistance of a cultural 
representative who can support the conversation by 
translating a family’s needs to a clinician.
Limitations/Challenges
Research involving patients with DoC is hampered by 
multiple factors, including the following:
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  • Early WLST in patients who would otherwise go on 
to attain significant recovery of function.
  • Discriminatory payer policies limit access to special-
ized post-acute-care facilities that have been shown 
to reduce complications in patients with DoC.
  • Variability in clinician knowledge and approach to 
communicating prognostic information may nega-
tively impact caregiver understanding, further 
increasing the probability of early withdrawal of 
aggressive treatment.
  • Difficulty integrating data from different systems of 
care that are not comparable and do not permit data 
sharing.
  • Ethical implications of clinical trial participation for 
long-term recovery of DoC.
  • Limited and regionally variable psychosocial support 
for caregivers following discharge from the acute care 
setting. Some consumer-created, well-organized car-
egiver support and advocacy groups do exist; how-
ever, most resources are available for patients with 
TBI rather than for those with non-TBI. The impact 
of advocacy groups in promoting access to care has 
not been formally studied and remains unknown.
Deliverables
Deliverables include (1) determining the natural history 
of recovery from DoC across the lifetime, (2) identifying 
accurate biomarkers and clinical predictors of favorable 
and unfavorable outcome, and (3) understanding the 




Large data sets, or databases, can help address multifac-
eted challenges of DoC research, which includes medical, 
scientific, technical, ethical, and social dimensions. Large 
data sets will help coma researchers by (1) fostering inter-
national consensus on issues such as definitions, causes, 
and confounders of DoC through implementation of 
CDEs [156]; (2) facilitating the design of operative diag-
nostic tools and meaningful outcome time points [157]; 
(3) enabling better research, including epidemiological 
studies that take advantage of between-center differences 
that explore processes of care and structural/organiza-
tional factors that may impact outcome and treatment 
heterogeneity effects [158–160]; (4) organizing and 
federating an international network of coma scientists 
who share a common language and connection [100]; 
(5) improving patient care by standardizing results and 
improving expertise [161]; and (6) helping family mem-
bers and caregivers of patients with coma provide better 
decision-making tools based on improved knowledge of 
acute- and post-acute-care trajectories [162]. A survey 
of the Scientific Advisory Council of the Curing Coma 
Campaign and the broader NCS found that clinicians 
and investigators’ interests focus on research involving 
patients affected by coma and acute DoC. These individ-
uals generally have access to clinical data but lack access 
to other data types (e.g., anatomical data, clinical out-
comes, safety).
The panelists surveyed current data sets to deter-
mine whether existing resources could be expanded or 
absorbed into a large international data set (see Table 1). 
Currently available resources are almost exclusively lim-
ited to patients with TBI or cardiac arrest. Available 
limited international data are disease specific (e.g., TBI, 
seizures), with relatively small numbers of patients with 
coma; moreover, these data pay little attention to the ori-
gins of DoC (e.g., toxic metabolic). 
Main Research Gap
Limited large data sets of patients with DoC exist at this 
time. Gaps in available data sets include limited imag-
ing and electrophysiologic data, lack of CDEs tailored to 
DoC, focus on primary disease states (i.e., TBI, intracer-
ebral hemorrhage, etc.) rather than coma, lack of applica-
ble biomarkers for coma and DoC, fragmented acute and 
chronic care data, and regional data restricted primarily 
to the United States and Europe. The key challenges to 
creating a large coma science data set are lack of uniform 
global data standards and collection across both substan-
tive measures (i.e., what is collected) and data handling 
and storage mode.
The overall goal is to gain insights into mechanisms, 
predictors, and trajectory of recovery and lay the founda-
tion for interventional trials by creating a large interna-
tional data set of patients with DoC.
Panel Discussion of the Approach
  • To accomplish this goal, researchers must develop 
a database that incorporates the following: a high-
throughput neuroinformatics platform [163] with 
real-time clinical and research input, automated 
imaging segmentation and analytical tools for quan-
tification [164], remote computation and Web-based 
user interfaces, a biobank, long-term follow-up data, 
data sharing agreements, and an international open 
access governance structure.
  • Such a database would seek to capture data that cover 
the trajectory of the disorder. This scope may require 
enrolling healthy populations to track patients who 
experience DoC from initial onset to death in a lon-











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































  • The database would collect clinically meaningful data 
at standardized intervals in real time and provide 
space for raw data (e.g., neuroimaging, neurophysi-
ology, serological, pathological, multimodal). The 
associated biobank would collect clinically meaning-
ful samples at standardized intervals using standard-
ized practices (i.e., sampling, handling, processing) 
for delivery to a centralized repository with disaster-
proof storage. The biobank may include a brain bank 
for whole-brain specimens.
  • The database platform should be automated for real-
time data input into a structured data architecture. 
Automation requires no manual data entry; instead, 
a tool would retrieve information from standard-
ized electronic health records. The database should 
require only periodic human maintenance, with 
manual validation of archived data to ensure reli-
ability. Statistical control processes existing in other 
industries would be used to check data quality for 
completeness and consistency.
  • Its governance model, which would aim to promote 
equal stakeholder access, would include a central 
oversight board and incorporate FAIR (Findable, 
Accessible, Interoperable, Reusable) and open sci-
ence principles. Any legal liability for using the data-
base would lie with the end user, but oversight would 
discourage unethical use.
  • The database should be accessible through an open 
access, secure Internet-based interface that would 
be intuitive and user-friendly. The output should be 
flexible to allow for project-specific programming by 
the end user. In cases in which project-specific pro-
grams may prove useful to the community at large, 
the platform may also incorporate new technologies 
developed by individual users. A federated approach 
for data archival, analysis, and result sharing would 
be ideal.
  • Initial steps: The Curing Coma Campaign is not 
currently prepared to create such a complex system 
without a robust foundational framework. (1) To 
start, a deep and broad survey of the current database 
landscape is needed to provide a better understand-
ing of what resources are available and which require 
creation. (2) In parallel, CDEs must be defined. (3) 
Once language, resources, wants, and needs are 
established, a simple database to obtain data from 
patients with coma can be built that begins stand-
ardizing data input and structure, types of patients 
and disorders covered, and current diagnostic and 
management strategies. (4) Once the initial database 
is established, existing frameworks could guide its 
expansion (e.g., the Alzheimer’s Disease Neuroimag-
ing Initiative [166] and Transforming Research and 
Clinical Knowledge in Traumatic Brain Injury [167]) 
to include increasingly complex data and automated 
data input. (5) The final result will be a comprehen-
sive international repository for research on coma 
and DoC. This ultimate version of the database must 
balance comprehensiveness and flexibility to incor-
porate future progress as the field advances its under-
standing.
Limitations/Challenges
There are several major challenges for creating an inter-
national data set:
  • The integration of data from different countries [168] 
by using a variety of data collection platforms (i.e., 
electronic medical vs. traditional paper records) [99].
  • Data elements need to be harmonized.
  • Long-term data capture will require infrastructures 
that may otherwise not be available globally.
  • The Curing Coma Campaign will need to create 
guidance for updating and upgrading both the tech-
nology and the clinical practices of global sites treat-
ing patients with coma.
  • Existing databases do not specifically address DoC or 
coma and will require careful data mining but may 
provide a launching point for the larger database. 
Thus, another approach is to start to collate existing 
neurological research databases.
  • Balancing simplicity to allow for global access 
and data entry, with complexity and depth of data 
required to address scientific questions: researchers 
will need to leverage innovative technology to create 
a self-maintained system that can retrieve data from 
electronic medical records and laboratory reports 
and make it accessible and available globally.
  • Lack of data sharing and master trial agreements may 
require Curing Coma Campaign researchers to assist 
sites with their creation to match the new technolog-
ical requirements.
  • Obtaining funding for this enterprise will require 
government support and global lobbying.
Deliverables
Deliverables include (1) creation of data dictionaries 
based on CDEs, common language and terminology, and 
data structure framework and (2) a large simple inter-
national database on patients with DoC that is built on 
CDEs.
Overall Conclusion
The level of engagement during the first NIH symposium of 
the Curing Coma Campaign supports the conclusion that 
this was a major success. The gaps, goals, approaches, and 
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deliverables outlined above are a direct result of the sym-
posium and provide an actionable path for the campaign 
toward achieving its overall goal of curing coma. Research 
efforts will require close communication and coordination 
between those focusing on clinical, translational, preclini-
cal, and basic science aspects of coma science to make great 
advances and cure coma. Future meetings are planned and 
will focus on additional areas of high importance for the 
Curing Coma Campaign, such as ethical implications of 
DoC research and the development of CDEs.
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